Table 2.

Inclusion and exclusion criteria for the study

Inclusion Criteria

1. Age 50 years old or older

2. Left ventricular ejection fraction (EF) ≥ 50% documented by an echocardiogram within 12 months of enrollment

3. Diagnosis of HFpEF within a 12-month period

4. Symptoms of dyspnea and New York Heart Association (NYHA) Classification II-or greater symptoms, and a diagnosis of HFpEF defined by ONE of the following:

4a. Previous hospitalization for HF with radiographic evidence (pulmonary venous hypertension, vascular congestion, interstitial edema, or pleural effusion) of pulmonary congestion

4b. Invasive hemodynamics

4c. Echocardiographic evidence of diastolic dysfunction

4d. Elevated NT-proBNP (>  400 pg/mL) or BNP (>  200 pg/mL)

4e. No use of intermittent sublingual nitroglycerin within 12 months

5. Willingness to provide informed consent

6. Have a telephone or reliable phone contact

7. Have their own means of transportation to the study site

Exclusion Criteria

1. Acute coronary syndrome in the past 12 weeks

2. Severe valvular heart disease

3. Severe cardiac fibrosis (galectin-3 level > 26 ng/ml)

4. Constrictive pericardium

5. Pulmonary fibrosis

6. Congenital heart disease

7. Hypertrophic or infiltrative cardiomyopathy

8. Heart transplant

9. Left ventricular assist device

10. HF associated hospital admission or ED visit within past 30 days

11. Percutaneous coronary intervention in the last month

12. Renal (Creatinine > 3) and/or severe hepatic dysfunction

13. Severe cognitive impairment

14. No current consumption of any CoQ10 (ubiquinol) or D-ribose supplements